Clinical trial
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
NCT04669587
Study timeline
Study start (actual)2021-07-26Date precision: day
Registry last updated2022-03-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Estrogen Receptor-Positiveunresolved
HER2-Negativeunresolved
Locally Advanced Breast Cancerunresolved
Metastatic Breast Cancerunresolved
Interventions
ZB716DRUG
PalbociclibDRUG · verified · RxNorm: palbociclib
Sponsors & collaborators
EnhancedBio USA Inc.lead sponsor
Zenopharmcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04669587 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.